DSNKY - Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting | Benzinga
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSKYF) (OTC: DSNKY) released topline data from the TROPION-Breast01 phase 3 trial of datopotamab deruxtecan (Dato-DXd) in previously treated patients with inoperable or metastatic hormone receptor (HR) positive, HER2 low or negative breast cancer.
Dato-DXd demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival compared to the investigator's choice ...